Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Ines Pires da Silva
Site‐specific Response Patterns, Pseudoprogression, and Acquired Resistance in Patients With Melanoma Treated With Ipilimumab Combined With Anti–PD‐1 Therapy
Cancer
Cancer Research
Oncology
Related publications
Comment on ‘Efficacy and Toxicity of Treatment With the Anti-Ctla-4 Antibody Ipilimumab in Patients With Metastatic Melanoma After Prior Anti-Pd-1 Therapy’
British Journal of Cancer
Cancer Research
Oncology
Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies
JAMA Oncology
Cancer Research
Oncology
Comprehensive Molecular and Clinical Characterization of Asian Melanoma Patients Treated With Anti-Pd-1 Antibody
BMC Cancer
Cancer Research
Oncology
Genetics
Factors Influencing the Efficacy of Anti-Pd-1 Therapy in Chinese Patients With Advanced Melanoma
Journal of Oncology
Oncology
Fatal Myocarditis and Rhabdomyositis in a Patient With Stage IV Melanoma Treated With Combined Ipilimumab and Nivolumab
Current Oncology
Oncology
Corrigendum: Association of CTLA-4 Gene Variants With Response to Therapy and Long-Term Survival in Metastatic Melanoma Patients Treated With Ipilimumab: An Italian Melanoma Intergroup Study
Frontiers in Immunology
Allergy
Immunology
Panhypopituitarism in Metastatic Melanoma Patient Treated With Ipilimumab and Pembrolizumab
Journal of Cutaneous Immunology and Allergy
Safety and Tumor Responses With Lambrolizumab (Anti–PD-1) in Melanoma
New England Journal of Medicine
Medicine
Melanoma-Specific MHC-II Expression Represents a Tumour-Autonomous Phenotype and Predicts Response to Anti-Pd-1/Pd-L1 Therapy
Nature Communications
Astronomy
Genetics
Molecular Biology
Biochemistry
Chemistry
Physics
